On Nov. 29, 2022, Novavax announced that the World Health Organization had issued an updated Emergency Use Listing for Nuvaxovidﾙ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.